$REGN
Regeneron Pharmaceuticals Inc Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000153217615000029 Filed on August 04, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$998.6M	$665.7M
YoY Change	50.01%	45.46%
Cost Of Revenue	$60.86M	$29.95M
YoY Change	103.22%	9.76%
Gross Profit	$937.8M	$635.8M
YoY Change	47.5%	47.73%
Gross Profit Margin	93.91%	95.5%
Selling, General & Admin	$174.6M	$96.73M
YoY Change	80.49%	33.49%
% of Gross Profit	18.62%	15.21%
Research & Development	$390.3M	$294.5M
YoY Change	32.54%	57.1%
% of Gross Profit	41.62%	46.32%
Depreciation & Amortization	$15.30M	$13.00M
YoY Change	17.69%	34.02%
% of Gross Profit	1.63%	2.04%
Operating Expenses	$564.9M	$391.2M
YoY Change	44.39%	50.52%
Operating Profit	$344.9M	$228.1M
YoY Change	51.19%	44.27%
Interest Expense	$2.748M	$10.18M
YoY Change	-73.0%	-10.45%
% of Operating Profit	0.8%	4.46%
Other Income/Expense, Net	-$16.86M	-$19.29M
YoY Change	-12.57%	85.26%
Pretax Income	$328.0M	$208.8M
YoY Change	57.08%	41.38%
Income Tax	$133.4M	$112.5M
% Of Pretax Income	40.66%	53.86%
Net Earnings	$194.6M	$96.35M
YoY Change	102.01%	10.27%
Net Earnings / Revenue	19.49%	14.47%
Basic Earnings Per Share	$1.89	$0.96
Diluted Earnings Per Share	$1.69	$0.85
COMMON SHARES
Basic Shares Outstanding	102.9M shares	100.4M shares
Diluted Shares Outstanding	115.3M shares	113.0M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$604.0M	$817.0M
YoY Change	-26.07%	51.86%
Cash & Equivalents	$390.6M	$600.1M
Short-Term Investments	$214.0M	$217.0M
Other Short-Term Assets	$142.0M	$126.0M
YoY Change	12.7%	28.57%
Inventory	$171.3M	$109.9M
Prepaid Expenses
Receivables	$1.072B	$664.1M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.283B	$1.919B
YoY Change	19.0%	22.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.326B	$707.3M
YoY Change	87.48%	68.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$590.0M	$551.0M
YoY Change	7.08%	218.5%
Other Assets	$4.138M	$8.877M
YoY Change	-53.39%	-41.64%
Total Long-Term Assets	$2.244B	$1.537B
YoY Change	45.94%	88.2%
TOTAL ASSETS
Total Short-Term Assets	$2.283B	$1.919B
Total Long-Term Assets	$2.244B	$1.537B
Total Assets	$4.527B	$3.456B
YoY Change	30.99%	45.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$130.0M	$47.00M
YoY Change	176.6%	95.83%
Accrued Expenses	$399.0M	$236.0M
YoY Change	69.07%	82.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$601.5M	$351.6M
YoY Change	71.1%	72.51%
LONG-TERM LIABILITIES
Long-Term Debt	$388.0M	$517.0M
YoY Change	-24.95%	9.3%
Other Long-Term Liabilities	$76.08M	$14.97M
YoY Change	408.28%	46.75%
Total Long-Term Liabilities	$76.08M	$14.97M
YoY Change	408.28%	46.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$601.5M	$351.6M
Total Long-Term Liabilities	$76.08M	$14.97M
Total Liabilities	$1.189B	$1.087B
YoY Change	9.31%	22.86%
SHAREHOLDERS EQUITY
Retained Earnings	$487.3M	$65.49M
YoY Change	644.14%	-119.8%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$287.1M	-$43.85M
YoY Change	-754.71%
Treasury Stock Shares	3.417M shares	521.9K shares
Shareholders Equity	$3.338B	$2.369B
YoY Change
Total Liabilities & Shareholders Equity	$4.527B	$3.456B
YoY Change	30.99%	45.32%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	$194.6M	$96.35M
YoY Change	102.01%	10.27%
Depreciation, Depletion And Amortization	$15.30M	$13.00M
YoY Change	17.69%	34.02%
Cash From Operating Activities	$257.8M	$336.4M
YoY Change	-23.37%	162.4%
INVESTING ACTIVITIES
Capital Expenditures	-$239.9M	-$70.90M
YoY Change	238.36%	105.51%
Acquisitions
YoY Change
Other Investing Activities	-$131.8M	-$47.30M
YoY Change	178.65%	-131.3%
Cash From Investing Activities	-$371.6M	-$118.2M
YoY Change	214.38%	-201.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.500M	-80.10M
YoY Change	-95.63%	84.14%
NET CHANGE
Cash From Operating Activities	257.8M	336.4M
Cash From Investing Activities	-371.6M	-118.2M
Cash From Financing Activities	-3.500M	-80.10M
Net Change In Cash	-117.3M	138.1M
YoY Change	-184.94%	-31.4%
FREE CASH FLOW
Cash From Operating Activities	$257.8M	$336.4M
Capital Expenditures	-$239.9M	-$70.90M
Free Cash Flow	$497.7M	$407.3M
YoY Change	22.19%	150.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2013Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	16100000	USD
CY2014Q2	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	35100000	USD
CY2014Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	56200000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.64
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2492000	shares
CY2015Q2	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	67900000	USD
CY2014Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	41555000	USD
CY2015Q2	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	48084000	USD
CY2014Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	133085000	USD
	regn	Debt Conversion DebtConversion	144000000	USD
CY2015Q2	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	196095000	USD
CY2014Q2	regn	Costofmanufacturing Costofmanufacturing	16434000	USD
	regn	Costofmanufacturing Costofmanufacturing	32533000	USD
CY2015Q2	regn	Costofmanufacturing Costofmanufacturing	27985000	USD
	regn	Costofmanufacturing Costofmanufacturing	69370000	USD
	regn	Debt Conversion DebtConversion	61100000	USD
	regn	Decreaseintotalcashfromfinancing Decreaseintotalcashfromfinancing	8600000	USD
CY2014Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	15927000	USD
CY2015Q2	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	18026000	USD
CY2014Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	62819000	USD
CY2015Q2	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	46095000	USD
CY2014Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	310938000	USD
CY2015Q2	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	357687000	USD
	regn	Facilityleaseobligationrecognizedduringtheperiod Facilityleaseobligationrecognizedduringtheperiod	50600000	USD
	regn	Facilityleaseobligationrecognizedduringtheperiod Facilityleaseobligationrecognizedduringtheperiod	20100000	USD
	regn	Increaseintotalcashfromoperating Increaseintotalcashfromoperating	8600000	USD
CY2014Q2	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	405000	shares
	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	403000	shares
CY2015Q2	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	474000	shares
	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	471000	shares
	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived	500000000	USD
	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million	600000000	USD
	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million	700000000	USD
CY2014Q4	regn	Limitpricepershareforwarrantholderstocloseouthedgeposition Limitpricepershareforwarrantholderstocloseouthedgeposition	397.75
	regn	Lossonextinguishmentofdebt Lossonextinguishmentofdebt	16900000	USD
CY2014Q4	regn	Maximumreductionofwarrantsheldbywarrantholder Maximumreductionofwarrantsheldbywarrantholder	493229	shares
	regn	Numberofsalesmilestonepaymentsthe Companyreceived NumberofsalesmilestonepaymentstheCompanyreceived	3
CY2015Q1	regn	Numberofsalesmilestonepaymentsthe Companyreceived NumberofsalesmilestonepaymentstheCompanyreceived	1
CY2014Q2	regn	Other Collaboration Revenue OtherCollaborationRevenue	97295000	USD
	regn	Other Collaboration Revenue OtherCollaborationRevenue	222607000	USD
CY2015Q2	regn	Other Collaboration Revenue OtherCollaborationRevenue	134237000	USD
	regn	Other Collaboration Revenue OtherCollaborationRevenue	258083000	USD
	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2015Q1	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2014Q4	regn	Reductionin Apic ReductioninAPIC	14200000	USD
CY2014Q4	regn	Reductioninaccountsreceivable Reductioninaccountsreceivable	41000000	USD
CY2014Q4	regn	Reductionindeferredrevenue Reductionindeferredrevenue	41000000	USD
CY2014Q4	regn	Reductioninincometaxassetsnet Reductioninincometaxassetsnet	14200000	USD
	regn	Stockissuedduringperiodconversionofconvertiblenotes Stockissuedduringperiodconversionofconvertiblenotes	521876	shares
	regn	Stockissuedduringperiodconversionofconvertiblenotes Stockissuedduringperiodconversionofconvertiblenotes	1399069	shares
CY2014Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	125483000	USD
CY2015Q2	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	125767000	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	483489000	USD
CY2015Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	529505000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	99508000	USD
CY2015Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	130016000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	739379000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1071665000	USD
CY2014Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	111510000	USD
CY2015Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	197693000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	52251000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	19153000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2450782000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3118969000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	225283000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-114560000	USD
CY2014Q4	us-gaap	Assets Assets	3837672000	USD
CY2015Q2	us-gaap	Assets Assets	4526970000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	2130938000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	2283341000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	711915000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	81989000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1551000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	631477000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	31000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	1551000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	985000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	426941000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	454468000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1551000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	954000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	426941000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	446866000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	7602000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1128000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1102000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	360208000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	542369000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	251761000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	213694000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	613097000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	757165000	USD
CY2014Q2	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	1400000.0	USD
	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	1400000.0	USD
CY2015Q2	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-16300000.0	USD
	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-18902000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535608000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	600135000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	648719000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	390554000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	64527000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-258165000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	99149000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	170107000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	165892000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	237566000	USD
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	146773000	USD
CY2015Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	30360000	USD
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	7500000	USD
CY2015Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2000000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	29945000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	57418000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	60855000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	103425000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	437610000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	871788000	USD
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	537324000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1409112000	USD
CY2014Q4	us-gaap	Costs And Expenses CostsAndExpenses	586526000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	1995638000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	653758000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1239817000	USD
CY2015Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	33300000	USD
CY2011Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-27714000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	58098000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	51720000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	72430000	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	76748000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	46179000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	69603000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	269237000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	323784000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24546000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31325000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.65
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.47
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.36
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.89
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.98
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.35
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.46
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.19
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2014Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.539
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.577
CY2015Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.407
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.552
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.039
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	92778000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	83105000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	235575000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	248718000	USD
CY2014Q2	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2015Q2	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2015Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	91400000	USD
CY2014Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10787000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10787000	USD
CY2015Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15964000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-16906000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	208803000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	389689000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	181823000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	571512000	USD
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	189723000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	761235000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	327996000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	604519000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112452000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	225033000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	98448000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	323481000	USD
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	99628000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	423109000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	133353000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	333855000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16820000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	129338000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-84776000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	418753000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	19092000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	59069000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	16105000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-16685000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	37295000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	49852000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29446000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-33842000	USD
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2877000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	3018000	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2461000	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9359000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9615000	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9438000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9441000	shares
CY2014Q2	us-gaap	Interest Expense InterestExpense	10177000	USD
	us-gaap	Interest Expense InterestExpense	21790000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	2748000	USD
	us-gaap	Interest Expense InterestExpense	8917000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10768000	USD
CY2015Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9495000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	128861000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	171266000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10923000	USD
CY2015Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	20999000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	73519000	USD
CY2015Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	111564000	USD
CY2014Q2	us-gaap	Inventory Write Down InventoryWriteDown	800000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1900000	USD
CY2015Q2	us-gaap	Inventory Write Down InventoryWriteDown	6400000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	8100000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	1287421000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	1188512000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3837672000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4526970000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	654660000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	601542000	USD
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	7788000	USD
	us-gaap	Licenses Revenue LicensesRevenue	15330000	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	11451000	USD
	us-gaap	Licenses Revenue LicensesRevenue	39288000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	251761000	USD
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	213694000	USD
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	460154000	USD
CY2015Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	589595000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28942000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86861000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-354354000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-501130000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	389939000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	156104000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	96351000	USD
	us-gaap	Net Income Loss NetIncomeLoss	164656000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	83375000	USD
	us-gaap	Net Income Loss NetIncomeLoss	248031000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	90095000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	338126000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	194643000	USD
	us-gaap	Net Income Loss NetIncomeLoss	270664000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19287000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29963000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-16863000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23893000	USD
CY2013Q4	us-gaap	Notes Payable NotesPayable	0	USD
CY2014Q2	us-gaap	Notes Payable NotesPayable	0	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	228090000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	419652000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	188464000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	608116000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	215803000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	823919000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	344859000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	628412000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	116563000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	72205000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3034000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4138000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2798000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5451000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-28751000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-33098000	USD
CY2014Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	33651000	USD
CY2015Q2	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	29208000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	97146000	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2291000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39801000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	76080000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	10871000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	2745000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6598000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-17627000	USD
CY2014Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1677000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2614000	USD
CY2015Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1849000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1930000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	124000000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	143041000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	124531000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	64990000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	35930000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	374509000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	340844000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	135695000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	354055000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79046000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43099000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	63057000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	115825000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-534000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	26780000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	155850000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	193769000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	974309000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1326112000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	61125000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	144001000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	294501000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	581880000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	390330000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	733443000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	216644000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	487308000	USD
CY2014Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	142595000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	273103000	USD
CY2015Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	195110000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	368466000	USD
CY2014Q2	us-gaap	Revenues Revenues	665700000	USD
	us-gaap	Revenues Revenues	1291440000	USD
CY2015Q2	us-gaap	Revenues Revenues	998617000	USD
	us-gaap	Revenues Revenues	1868229000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	418022000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	780400000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	657819000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1202392000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	96730000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	199957000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	144003000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	343960000	USD
CY2014Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	175307000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	519267000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	174588000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	333579000	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	64828000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	140613000	USD
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	94257000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	198016000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2550251000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	3338458000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2017732	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	3416788	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	169530000	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	287079000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24601000	USD
CY2014Q2	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	25082000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24781000	USD
CY2015Q2	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45458000	USD
	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	51841000	USD
	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	83682000	USD
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	51360000	USD
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	63005000	USD
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12641000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13036000	shares
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12373000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12404000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113032000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113121000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115259000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114962000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100391000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100085000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102886000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102558000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued a new standard related to revenue recognition, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities. The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has not yet determined its method of transition and is evaluating the impact that this guidance will have on the Company's financial statements.</font></div></div>
	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, and other sales-related deductions. </font></div></div>

Files In Submission

Name	View Source	Status
0001532176-15-000029-index-headers.html	Edgar Link	pending
0001532176-15-000029-index.html	Edgar Link	pending
0001532176-15-000029.txt	Edgar Link	pending
0001532176-15-000029-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-063015x10q.htm	Edgar Link	pending
regn-20150630.xml	Edgar Link	completed
regn-20150630.xsd	Edgar Link	pending
regn-20150630_cal.xml	Edgar Link	unprocessable
regn-20150630_def.xml	Edgar Link	unprocessable
regn-20150630_lab.xml	Edgar Link	unprocessable
regn-20150630_pre.xml	Edgar Link	unprocessable
regn-ex_102x06302015x10q.htm	Edgar Link	pending
regn-ex_103x06302015x10q.htm	Edgar Link	pending
regn-ex_104x06302015x10q.htm	Edgar Link	pending
regn-ex_105x06302015x10q.htm	Edgar Link	pending
regn-ex_106x06302015x10q.htm	Edgar Link	pending
regn-ex_311x06302015x10q.htm	Edgar Link	pending
regn-ex_312x06302015x10q.htm	Edgar Link	pending
regn-ex_31x06302015x10q.htm	Edgar Link	pending
regn-ex_32x06302015x10q.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
Regeneron Pharmaceuticals Inc Stock $regn

2015 Q2 Form 10-Q Financial Statement

#000153217615000029 Filed on August 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN Regeneron Pharmaceuticals Inc Stock $regn

2015 Q2 Form 10-Q Financial Statement

#000153217615000029 Filed on August 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
Regeneron Pharmaceuticals Inc Stock $regn